ischemia/hypoxia

TECHNICAL FIELD OF THE INVENTION This invention relates to pharmaceutical compositions useful for treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration, and to methods for using the compositions. BACKGROUND OF THE INVENTION Neurotrophic factors exhibit a trophic effect

The present invention relates to therapeutically active piperidine compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the treatment of anoxia, traumatic injury, ischemia, migraine and epilepsy. It is well known

This application is a 371 of PCT/FR 43/00312 filed Mar. 29, 1993. FIELD OF THE INVENTION The present invention relates to a novel therapeutic application of the phenothiazine derivatives of general formula: ##STR2## in which: the symbol R is an alkyl radical containing 1 to 5 carbon atoms in a

FIELD OF THE INVENTION The present invention relates generally to a method for modulating the inflammatory response induced in a mammal following tissue injury. More particularly, this invention relates to a method for alleviating immune-cell mediated tissue destruction associated with the

FIELD OF THE INVENTION Modifications to various proteins including, but not limited to, proteins involved in the tricarboxylic acid (TCA) cycle, oxidative phosphorylation (OxPhos) pathways, calcium (Ca.sup.2+) handling, and/or chaperoning, as well as proteins selected from aldehyde dehydrogenase,

BACKGROUND OF THE INVENTION 1. Technical Field The present invention relates to the identification of genes that are differentially expressed in hypoxia and use of the genes and gene products for diagnosis and therapeutic intervention. The invention further relates to identification of

BACKGROUND OF THE INVENTION 1. Technical Field The present invention relates to the identification of genes that are differentially expressed in hypoxia and use of the genes and gene products for diagnosis and therapeutic intervention. The invention further relates to identification of

BACKGROUND OF THE INVENTION The invention is in the fields of neurology and pharmacology and relates to protecting the brain and central nervous system against damage due to ischemia and other neurological disorders in which energy-providing substrates (oxygen and glucose) are reduced or energy

TECHNICAL FIELD The present invention relates to the use of N-acetyl-D-glucosamine and pharmaceutical acceptable salts thereof in the manufacture of a medicament for resisting cardiac and cerebral ischemia as well as oxygen-deficiency. BACKGROUND ART The cardiac and cerebral ischemia as well as

BACKGROUND OF THE INVENTION This invention relates to the use of glycogen phosphorylase inhibitors to reduce tissue damage resulting from non-cardiac ischemia in mammals, including human patients. Glycogen phosphorylase inhibitors constitute a class of compounds which have use in the treatment of

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is directed to methods for preconditioning and/or providing neuroprotection to the animal central nervous system against ischemia, neurodegeneration, trauma and metal poisoning, including associated cognitive, behavioral and

TECHNICAL FIELD The present invention relates to compositions comprising hypoxia inducible factor-1 alpha (HIF-1.alpha.) and methods of treating hypoxia or ischemia. BACKGROUND In mammals, embryo development and maintenance of adult homeostatsis depend on the establishment of a functional vascular

FIELD OF THE INVENTION The present invention relates to the field of medicine. It provides new compositions and methods for treating or protecting individuals in need thereof from cerebral ischemia or hypoxia. The invention also relates to new compositions and methods for treating stroke. More

BACKGROUND OF INVENTION This invention relates to adenosine A-3 receptor agonists, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat for example, ischemia particularly, perioperative myocardial ischemic injury in mammals, including humans. Mycardial

BACKGROUND OF THE INVENTION The eye, like other parts of the central nervous system, has limited regeneration capability. Thus, many ocular diseases and injuries such as retinal photic injury, retinal ischemia-reperfusion induced eye injury, chronic intermittent hypoxia related eye injury,